Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Average Recommendation of “Hold” from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) have earned an average rating of “Hold” from the thirteen research firms that are covering the stock, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.25.

A number of brokerages have recently issued reports on FUSN. Bloom Burton downgraded Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Raymond James reaffirmed a “market perform” rating on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Leerink Partnrs downgraded Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 19th. Brookline Capital Management cut Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $21.00 price objective (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th.

Fusion Pharmaceuticals Stock Performance

Fusion Pharmaceuticals stock opened at $21.30 on Thursday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -14.49 and a beta of -0.85. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. Fusion Pharmaceuticals has a 12 month low of $2.31 and a 12 month high of $21.44. The business’s fifty day simple moving average is $12.45 and its two-hundred day simple moving average is $7.66.

Institutional Trading of Fusion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. increased its position in Fusion Pharmaceuticals by 1.9% in the fourth quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock worth $104,616,000 after buying an additional 202,364 shares in the last quarter. Avidity Partners Management LP increased its position in Fusion Pharmaceuticals by 12.4% in the fourth quarter. Avidity Partners Management LP now owns 6,500,328 shares of the company’s stock worth $62,468,000 after buying an additional 718,478 shares in the last quarter. FMR LLC increased its position in Fusion Pharmaceuticals by 73.9% in the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after buying an additional 1,989,403 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Fusion Pharmaceuticals in the first quarter worth about $10,405,000. Finally, Sphera Funds Management LTD. increased its position in Fusion Pharmaceuticals by 3.6% in the second quarter. Sphera Funds Management LTD. now owns 1,329,258 shares of the company’s stock worth $6,208,000 after buying an additional 45,721 shares in the last quarter. Hedge funds and other institutional investors own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.